KRTX - Karuna Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
Total Revenue
0
0
0
Cost of Revenue
-
-
-
Gross Profit
-
-
-
Operating Expenses
Research Development
26,264
11,536
3,616
Selling General and Administrative
18,421
2,974
1,190
Total Operating Expenses
44,685
14,510
4,806
Operating Income or Loss
-44,685
-14,510
-4,806
Interest Expense
1,136
2,583
1,171
Total Other Income/Expenses Net
-150
-444
-55
Income Before Tax
-44,510
-17,512
-6,032
Income Tax Expense
0
0
0
Income from Continuing Operations
-44,510
-17,512
-6,032
Net Income
-44,510
-17,512
-6,032
Net Income available to common shareholders
-44,510
-17,512
-6,032
Reported EPS
Basic
-
-2.36
-0.81
Diluted
-
-2.36
-0.81
Weighted average shares outstanding
Basic
-
7,421
7,421
Diluted
-
7,421
7,421
EBITDA
-
-14,923
-4,860